<DOC>
	<DOCNO>NCT00207701</DOCNO>
	<brief_summary>A study safety efficacy Infliximab ( Remicade ) versus placebo subject Ankylosing Spondylitis</brief_summary>
	<brief_title>A Study Infliximab ( Remicade ) Patients With Ankylosing Spondylitis .</brief_title>
	<detailed_description>This clinical research study determine reduction sign symptom ( back pain stiffness ) patient ankylose spondylitis infliximab therapy . This study also study safety infliximab patient ankylose spondylitis . The effect infliximab physical function , damage joint quality life patient ankylose spondylitis also study . Subjects receive infusion either placebo week 0 , 2 , 6 , 12 , 18 5 mg/kg infliximab week 24 , 26 , 30 every 6 week week 96 , 5 mg/kg infliximab week 1 , 2 , 6 , 12 , 18 every 6 week week 96</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Have diagnosis definite Akylosing Spondylitis least 3 month prior screen Have active disease spinal pain receive intolerant standard antiinflammatory agent Have Rheumatoid Arthritis , systemic lupus erythematosus , inflammatory rheumatic disease Have document history fibromyalgia Have total ankylosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Ankylosing Spondylitis</keyword>
	<keyword>infusion</keyword>
</DOC>